Performance of Cytokine Models in Predicting SLE Activity

Overview

Journal Arthritis Res Ther

Publisher Biomed Central

Specialty Rheumatology

Date 2019 Dec 18

PMID 31842967

Citations 29

Authors

Nopparat Ruchakorn

Pintip Ngamjanyaporn

Thanitta Suangtamai

Thanuchporn Kafaksom

Charin Polpanumas

Veerachat Petpisit

Trairak Pisitkun

Prapaporn Pisitkun

Affiliations

Soon will be listed here.

Abstract

Background: Identification of universal biomarkers to predict systemic lupus erythematosus (SLE) flares is challenging due to the heterogeneity of the disease. Several biomarkers have been reported. However, the data of validated biomarkers to use as a predictor for lupus flares show variation. This study aimed to identify the biomarkers that are sensitive and specific to predict lupus flares.

Methods: One hundred and twenty-four SLE patients enrolled in this study and were prospectively followed up. The evaluation of disease activity achieved by the SLE disease activity index (SLEDAI-2K) and clinical SLEDAI (modified SLEDAI). Patients with active SLE were categorized into renal or non-renal flares. Serum cytokines were measured by multiplex bead-based flow cytometry. The correlation and logistic regression analysis were performed.

Results: Levels of IFN-α, MCP-1, IL-6, IL-8, and IL-18 significantly increased in active SLE and correlated with clinical SLEDAI. Complement C3 showed a weakly negative relationship with IFN-α and IL-18. IL-18 showed the highest positive likelihood ratios for active SLE. Multiple logistic regression analysis showed that IL-6, IL-8, and IL-18 significantly increased odds ratio (OR) for active SLE at baseline while complement C3 and IL-18 increased OR for active SLE at 12 weeks. IL-18 and IL-6 yielded higher sensitivity and specificity than anti-dsDNA and C3 to predict active renal and active non-renal, respectively.

Conclusion: The heterogeneity of SLE pathogenesis leads to different signaling mechanisms and mediates through several cytokines. The monitoring of cytokines increases the sensitivity and specificity to determine SLE disease activity. IL-18 predicts the risk of active renal SLE while IL-6 and IL-8 predict the risk of active non-renal. The sensitivity and specificity of these cytokines are higher than the anti-dsDNA or C3. We propose to use the serum level of IL-18, IL-6, and IL-8 to monitor SLE disease activity in clinical practice.

Citing Articles

Cardiovascular disease risk in Korean patients with systemic lupus erythematosus compared to diabetes mellitus and the general population.

Han J, Cho S, Jeon Y, Kang G, Jung S, Jang E Sci Rep. 2025; 15(1):3208.

PMID: 39863730 PMC: 11762264. DOI: 10.1038/s41598-025-87740-y.

Machine learning identifies cytokine signatures of disease severity and autoantibody profiles in systemic lupus erythematosus - a pilot study.

Pattanaik S, Das B, Tripathy R, Prusty B, Parida M, Tripathy S Sci Rep. 2024; 14(1):28765.

PMID: 39567666 PMC: 11579361. DOI: 10.1038/s41598-024-79978-9.

Evaluation of disease activity in systemic lupus erythematosus using standard deviation of lymphocyte volume combined with red blood cell count and lymphocyte percentage.

Zhao J, Peng W, Wu S, Wang W Sci Rep. 2024; 14(1):22470.

PMID: 39341869 PMC: 11439007. DOI: 10.1038/s41598-024-72977-w.

CD9 and Aryl Hydrocarbon Receptor Are Markers of Human CD19+CD14+ Atypical B Cells and Are Dysregulated in Systemic Lupus Erythematous Disease.

Blevins L, Khan D, Crawford R, ONeill C, Bach A, Zhou J J Immunol. 2024; 213(8):1076-1092.

PMID: 39212542 PMC: 11458359. DOI: 10.4049/jimmunol.2400193.

The effect of circulating cytokines on the risk of systemic lupus erythematosus: Mendelian randomization and observational study.

Xue D, Qian Y, Tu X, He M, Xing F, Ren Y Immunogenetics. 2024; 76(5-6):315-322.

PMID: 39183206 PMC: 11496328. DOI: 10.1007/s00251-024-01351-x.

References

Thanadetsuntorn C, Ngamjanyaporn P, Setthaudom C, Hodge K, Saengpiya N, Pisitkun P . The model of circulating immune complexes and interleukin-6 improves the prediction of disease activity in systemic lupus erythematosus. Sci Rep. 2018; 8(1):2620. PMC: 5805742. DOI: 10.1038/s41598-018-20947-4. View

Talaat R, Mohamed S, Bassyouni I, Raouf A . Th1/Th2/Th17/Treg cytokine imbalance in systemic lupus erythematosus (SLE) patients: Correlation with disease activity. Cytokine. 2015; 72(2):146-53. DOI: 10.1016/j.cyto.2014.12.027. View

Jafari-Nakhjavani M, Abedi-Azar S, Nejati B . Correlation of plasma interleukin-18 concentration and severity of renal involvement and disease activity in systemic lupus erythematosus. J Nephropathol. 2016; 5(1):28-33. PMC: 4790184. DOI: 10.15171/jnp.2016.05. View

Hakkim A, Furnrohr B, Amann K, Laube B, Abu Abed U, Brinkmann V . Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci U S A. 2010; 107(21):9813-8. PMC: 2906830. DOI: 10.1073/pnas.0909927107. View

Baechler E, Batliwalla F, Karypis G, Gaffney P, Ortmann W, Espe K . Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A. 2003; 100(5):2610-5. PMC: 151388. DOI: 10.1073/pnas.0337679100. View

Arora V, Verma J, Marwah V, Kumar A, Anand D, Das N . Cytokine imbalance in systemic lupus erythematosus: a study on northern Indian subjects. Lupus. 2012; 21(6):596-603. DOI: 10.1177/0961203311434937. View

Saisoong S, Eiam-Ong S, Hanvivatvong O . Correlations between antinucleosome antibodies and anti-double-stranded DNA antibodies, C3, C4, and clinical activity in lupus patients. Clin Exp Rheumatol. 2006; 24(1):51-8. View

Jacob N, Stohl W . Cytokine disturbances in systemic lupus erythematosus. Arthritis Res Ther. 2011; 13(4):228. PMC: 3239336. DOI: 10.1186/ar3349. View

Theofilopoulos A, Koundouris S, Kono D, Lawson B . The role of IFN-gamma in systemic lupus erythematosus: a challenge to the Th1/Th2 paradigm in autoimmunity. Arthritis Res. 2001; 3(3):136-41. PMC: 128889. DOI: 10.1186/ar290. View

10.

Fu Q, Chen X, Cui H, Guo Y, Chen J, Shen N . Association of elevated transcript levels of interferon-inducible chemokines with disease activity and organ damage in systemic lupus erythematosus patients. Arthritis Res Ther. 2008; 10(5):R112. PMC: 2592795. DOI: 10.1186/ar2510. View

11.

Pisitkun P, Ha H, Wang H, Claudio E, Tivy C, Zhou H . Interleukin-17 cytokines are critical in development of fatal lupus glomerulonephritis. Immunity. 2012; 37(6):1104-15. PMC: 3594848. DOI: 10.1016/j.immuni.2012.08.014. View

12.

Fouad N, Baraka E, Hassan W . Interleukin-18 gene polymorphisms in systemic lupus erythematosus: relation to disease status. Egypt J Immunol. 2014; 21(1):1-12. View

13.

Fragoso-Loyo H, Richaud-Patin Y, Orozco-Narvaez A, Davila-Maldonado L, Atisha-Fregoso Y, Llorente L . Interleukin-6 and chemokines in the neuropsychiatric manifestations of systemic lupus erythematosus. Arthritis Rheum. 2007; 56(4):1242-50. DOI: 10.1002/art.22451. View

14.

Ohl K, Tenbrock K . Inflammatory cytokines in systemic lupus erythematosus. J Biomed Biotechnol. 2011; 2011:432595. PMC: 3196871. DOI: 10.1155/2011/432595. View

15.

Mejia-Vilet J, Cordova-Sanchez B, Arreola-Guerra J, Morales-BuenRostro L, Uribe-Uribe N, Correa-Rotter R . Renal flare prediction and prognosis in lupus nephritis Hispanic patients. Lupus. 2015; 25(3):315-24. DOI: 10.1177/0961203315606985. View

16.

Petri M, Orbai A, Alarcon G, Gordon C, Merrill J, Fortin P . Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012; 64(8):2677-86. PMC: 3409311. DOI: 10.1002/art.34473. View

17.

Jain S, Park G, Sproule T, Christianson G, Leeth C, Wang H . Interleukin 6 Accelerates Mortality by Promoting the Progression of the Systemic Lupus Erythematosus-Like Disease of BXSB.Yaa Mice. PLoS One. 2016; 11(4):e0153059. PMC: 4822786. DOI: 10.1371/journal.pone.0153059. View

18.

Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss D . Neutrophil extracellular traps kill bacteria. Science. 2004; 303(5663):1532-5. DOI: 10.1126/science.1092385. View

19.

Ho A, Barr S, Magder L, Petri M . A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus. Arthritis Rheum. 2001; 44(10):2350-7. DOI: 10.1002/1529-0131(200110)44:10<2350::aid-art398>3.0.co;2-a. View

20.

Lindau D, Ronnefarth V, Erbacher A, Rammensee H, Decker P . Nucleosome-induced neutrophil activation occurs independently of TLR9 and endosomal acidification: implications for systemic lupus erythematosus. Eur J Immunol. 2011; 41(3):669-81. DOI: 10.1002/eji.201040593. View